PMID: 8358572Jul 1, 1993

Effects of rolipram and siguazodan on the human isolated bronchus and their interaction with isoprenaline and sodium nitroprusside

British Journal of Pharmacology
Y QianCharles Advenier


1 The effects of the selective inhibitors of cyclic AMP phosphodiesterase type IV (rolipram) and type III (siguazodan) and their interactions with isoprenaline and sodium nitroprusside have been studied in the human isolated bronchus. 2 On bronchi under resting tone rolipram was, in terms of potency (pD2 = 7.77 +/- 0.14, n = 8), very similar to isoprenaline (pD2 = 7.31 +/- 0.12, n = 12) and salbutamol (pD2 = 7.12 +/- 0.17, n = 10) and approximately 10 fold more potent than siguazodan (pD2 = 6.80 +/- 0.12, n = 6). In terms of efficacy (Emax, expressed as percentage of maximal effect induced by theophylline 3 mM), both rolipram and siguazodan were less efficient (Emax = 74 +/- 6.7%, n = 8 and 66 +/- 7.5%, n = 6, respectively) than isoprenaline (Emax = 98 +/- 0.4%, n = 12) and salbutamol (Emax = 83 +/- 2.4%, n = 10). 3 During precontraction induced by methacholine (3 x 10(-7) M) or acetylcholine (10(-3) M), concentration-response curves to rolipram and siguazodan were shifted to the right and maximal effects reduced. Rolipram was more potent than siguazodan and, in terms of efficacy, it was less active. 4. Rolipram 10(-8) and 10(-7) M but not siguazodan potentiated the effects of isoprenaline as shown by the shift to the left of t...Continue Reading


Oct 1, 1992·British Journal of Pharmacology·I P HallK Daykin
Dec 1, 1991·Naunyn-Schmiedeberg's Archives of Pharmacology·C SchudtV Ullrich
Nov 1, 1990·The Journal of Allergy and Clinical Immunology·C P NielsonR Heaslip
Apr 1, 1990·Trends in Pharmacological Sciences·J A Beavo, D H Reifsnyder
Apr 1, 1980·British Journal of Pharmacology·D IakovidisC Raper
Oct 1, 1982·European Journal of Clinical Pharmacology·C G Löfdahl, N Svedmyr
Oct 1, 1984·British Journal of Clinical Pharmacology·C G Löfdahl, N Svedmyr
Apr 1, 1993·The Journal of Pharmacy and Pharmacology·Y ZhangCharles Advenier


Oct 1, 1994·Trends in Pharmacological Sciences·T J Torphy
Jan 1, 1995·The International Journal of Biochemistry & Cell Biology·D Raeburn, Charles Advenier
May 7, 1998·European Journal of Pharmacology·J M PlanquoisS G Dahl
Mar 11, 1998·Clinical and Experimental Pharmacology & Physiology·M TanizawaK Takagi
Aug 1, 1995·Thorax·A J Knox, A E Tattersfield
Aug 2, 2000·Respiratory Medicine·S Thirstrup
May 14, 2016·British Journal of Pharmacology·R Venkatasamy, D Spina
Mar 10, 1999·The American Journal of Physiology·C K BillingtonI P Hall
Jan 1, 1995·The Journal of Asthma : Official Journal of the Association for the Care of Asthma·J W Jenne
Aug 12, 1999·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·P DemolyJ Bousquet
Jul 28, 1999·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·D SchmidtK F Rabe
Nov 5, 2020·Fundamental & Clinical Pharmacology·Hélène SalvatorPhilippe Devillier

Related Concepts

SK&F 94836
Lobar Bronchus Structure
Smooth Muscle
Phosphodiesterase Inhibitors

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.